Investing.com - Financial Markets Worldwide

Vertex Pharmaceuticals Inc DRC (VRTX34)

B3
Symbol
Exchange
Currency
VRTX34·B3·BRL
VRTX·NASDAQ·USD
VRTX·Mexico·MXN
1VRTX·Milan·EUR
VRTX·TradeGate·EUR
VRTX·Frankfurt·EUR
VRTX·Vienna·EUR
Currency in BRL
652.80
+3.94(+0.61%)
Closed·

VRTX34 Financial Summary

Key Ratios

P/E Ratio-112.45
Price/Book6.73
Debt / Equity10%
Return on Equity-5.64%
Dividend Yield0.00%
EBITDA4.77B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa6,205.77,574.48,930.79,869.211,020.1
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa3,824.54,732.45,323.15,444.16,024.3
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa3,0543,892.34,378.44,307.54,592.6
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa2,711.72,342.13,3223,619.6-535.6
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa11,751.813,432.518,150.922,730.222,533.2
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa1,877.52,1422,742.13,547.43,564.6
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa8,686.810,10013,912.717,580.416,409.6
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa2,231.682,402.253,307.453,510.132,725.55
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa3,253.52,643.54,129.93,537.3-492.6
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa99.4-340.9-321.1-3,141.7-3,770
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-505.3-1,478-67.7-562.2-1,494.9
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa2,868.2811.23,711.9-139.7-5,800.1
* In Millions of USD (except for per share items)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
2.49 / --
Revenue / Forecast
2.77B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Vertex Pharmaceuticals DRC's earnings for the latest quarter?

The Vertex Pharmaceuticals DRC EPS (TTM) is -3.84. Vertex Pharmaceuticals DRC reported sales of 2,770.20, net income of 646.30, and EPS of 2.49 for the latest quarter.

What was Vertex Pharmaceuticals DRC's net income for the latest quarter?

Vertex Pharmaceuticals DRC's net income for the latest quarter was 646.30.

How did Vertex Pharmaceuticals DRC's performance compare year-over-year in the latest quarter?

The company's revenue moved from 2,912.00 in the previous quarter to 2,770.20 in the latest quarter, and net income moved from 913.00 to 646.30 compared to the previous quarter.

What is Vertex Pharmaceuticals DRC's net profit margin on a TTM basis?

Vertex Pharmaceuticals DRC's trailing twelve months (TTM) net profit margin is -4.86%.

How does Vertex Pharmaceuticals DRC's debt to equity ratio compare to industry standards?

Vertex Pharmaceuticals DRC's total debt-to-equity ratio is 10.00%.

What is Vertex Pharmaceuticals DRC's return on investment on a TTM basis?

Vertex Pharmaceuticals DRC's trailing twelve months (TTM) return on investment (ROI) is -5.64%.

Did Vertex Pharmaceuticals DRC gain or lose cash last quarter?

In the latest quarter, Vertex Pharmaceuticals DRC's net change in cash was 113.20 million.

What were Vertex Pharmaceuticals DRC's total assets and liabilities in the latest quarter?

As of the latest quarter, Vertex Pharmaceuticals DRC reported total assets of 22,880.50 million and total liabilities of 3,783.20 million.

How has Vertex Pharmaceuticals DRC's total revenue grown this year?

Vertex Pharmaceuticals DRC's total revenue was 2,912.00 in the previous quarter and 2,770.20 in the latest quarter.

What is Vertex Pharmaceuticals DRC's gross margin on a TTM basis?

Vertex Pharmaceuticals DRC's trailing twelve months (TTM) gross margin is 53.09%.

What was Vertex Pharmaceuticals DRC's revenue per share for the latest quarter?

Vertex Pharmaceuticals DRC's revenue per share for the latest quarter was 52.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.